Literature DB >> 2822754

Ketoconazole reverses hyperandrogenism in a patient with insulin resistance and acanthosis nigricans.

G M Pepper1, L Poretsky, J L Gabrilove, M M Ariton.   

Abstract

We administered ketoconazole to a young woman with ovarian hyperandrogenism, insulin resistance, and acanthosis nigricans. While taking ketoconazole, her serum testosterone, androstenedione, dehydroepiandrosterone, and cortisol levels declined, while serum progesterone, 17-hydroxyprogesterone, and 11-deoxycortisol rose. Serum LH, FSH, and estradiol levels were intermittently higher during ketoconazole treatment, although LH and FSH responsiveness to GnRH did not change. Basal and stimulated serum insulin concentrations were high before and during ketoconazole therapy, while fasting glucose levels and glucose disappearance rate constants were normal throughout the study. A dramatic improvement in hirsutism occurred, and menses resumed after a 6-yr hiatus. Adverse drug effects or clinical evidence of adrenal insufficiency were not encountered. These results support a role for ketoconazole in the therapy of ovarian hyperandrogenism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822754     DOI: 10.1210/jcem-65-5-1047

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  Low-dose ketoconazole treatment in hirsute women.

Authors:  N Sonino; C Scaroni; A Biason; M Boscaro; F Mantero
Journal:  J Endocrinol Invest       Date:  1990-01       Impact factor: 4.256

2.  Inhibition of human adrenal androgen secretion by ketoconazole.

Authors:  M M Weber; P Luppa; D Engelhardt
Journal:  Klin Wochenschr       Date:  1989-07-17

3.  Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome.

Authors:  A Vidal-Puig; M Muñoz-Torres; C Garcia-Calvente; E Jodar-Gimeno; P Lardelli; M E Ruiz-Requena; F Escobar-Jiménez
Journal:  J Endocrinol Invest       Date:  1994-09       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.